Published in:
01-11-2017 | Original Article
Liver Function Assessment Using Albumin–Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation
Published in: Digestive Diseases and Sciences | Issue 11/2017
Login to get accessAbstract
Background/Aim
Assessment of liver function is essential for management of hepatocellular carcinoma (HCC). Recently, albumin–bilirubin (ALBI) grade has been reported as a useful tool for assessing hepatic reserve in patients with HCC. The objective of this study was to determine whether ALBI grade could be used to predict the overall survival of very early-stage HCC patients treated with radiofrequency ablation (RF ablation).
Methods
A cohort of 368 patients with very early-stage HCC treated with RF ablation was retrospectively analyzed. The overall survival and recurrence-free survival were calculated in groups classified by ALBI grade and Child–Pugh score.
Results
Overall survival of patients with ALBI grade 1 was better than that of patients with ALBI grade 2 (5-year survival rate 88.5 vs. 73.8%, P < 0.001). In multivariable-adjusted model, ALBI grade was found to be an independent factor associated with overall survival (hazard ratio 2.44; 95% confidence interval 1.43–4.15). ALBI grade was able to stratify patients with distinct overall survival among patients within the same Child–Pugh score (5-year survival rate for Child–Pugh score 5: 88.5 vs. 76.6%, P = 0.002; for Child–Pugh score 6: 88.9 vs. 70.1%, P = 0.064). In contrast, Child–Pugh score was unable to stratify patients with distinct overall survival within the same ALBI grade.
Conclusions
Among patients with very early-stage HCC treated with RF ablation, ALBI grade was a good stratifying biomarker. ALBI grade was better tool for assessing liver function than Child–Pugh score for very early-stage HCC treated with RF ablation.